Pulmonx (NASDAQ:LUNG) Earns “Buy” Rating from D. Boral Capital

Pulmonx (NASDAQ:LUNG)‘s stock had its “buy” rating reissued by stock analysts at D. Boral Capital in a research note issued to investors on Thursday,Benzinga reports. They currently have a $14.00 target price on the stock.

A number of other brokerages also recently commented on LUNG. Weiss Ratings reissued a “sell (e+)” rating on shares of Pulmonx in a research report on Thursday, January 22nd. Canaccord Genuity Group decreased their price objective on shares of Pulmonx from $6.00 to $5.00 and set a “buy” rating for the company in a research report on Thursday, March 5th. Four research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, Pulmonx has a consensus rating of “Hold” and a consensus price target of $5.38.

Pulmonx Stock Up 5.5%

Shares of LUNG stock opened at $1.35 on Thursday. The company has a current ratio of 5.07, a quick ratio of 4.28 and a debt-to-equity ratio of 0.68. Pulmonx has a 1 year low of $1.13 and a 1 year high of $3.89. The firm’s fifty day moving average price is $1.44 and its two-hundred day moving average price is $1.71. The firm has a market capitalization of $57.02 million, a P/E ratio of -1.04 and a beta of 0.18.

Pulmonx (NASDAQ:LUNG) last issued its quarterly earnings results on Wednesday, April 29th. The company reported ($0.33) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.33). Pulmonx had a negative net margin of 60.09% and a negative return on equity of 87.11%. The firm had revenue of $20.59 million for the quarter, compared to analyst estimates of $20.43 million. On average, equities analysts predict that Pulmonx will post -1.12 EPS for the current fiscal year.

Insider Transactions at Pulmonx

In other Pulmonx news, CEO Glendon E. French III sold 67,813 shares of the business’s stock in a transaction dated Monday, March 2nd. The shares were sold at an average price of $1.43, for a total value of $96,972.59. Following the completion of the sale, the chief executive officer owned 1,409,511 shares of the company’s stock, valued at $2,015,600.73. The trade was a 4.59% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Over the last ninety days, insiders have sold 98,265 shares of company stock valued at $140,519. Insiders own 6.80% of the company’s stock.

Institutional Trading of Pulmonx

A number of institutional investors have recently bought and sold shares of LUNG. XTX Topco Ltd bought a new stake in Pulmonx in the 2nd quarter valued at about $149,000. Norges Bank bought a new stake in Pulmonx in the 2nd quarter valued at about $392,000. Jane Street Group LLC boosted its holdings in Pulmonx by 3,328.7% in the 2nd quarter. Jane Street Group LLC now owns 88,631 shares of the company’s stock valued at $230,000 after purchasing an additional 86,046 shares during the period. Bank of America Corp DE boosted its holdings in Pulmonx by 556.6% in the 2nd quarter. Bank of America Corp DE now owns 481,268 shares of the company’s stock valued at $1,246,000 after purchasing an additional 407,971 shares during the period. Finally, SG Americas Securities LLC boosted its holdings in Pulmonx by 95.8% in the 3rd quarter. SG Americas Securities LLC now owns 24,863 shares of the company’s stock valued at $40,000 after purchasing an additional 12,166 shares during the period. Institutional investors own 91.04% of the company’s stock.

Pulmonx Company Profile

Pulmonx Corporation is a commercial-stage medical device company focused on bronchoscopic lung volume reduction for patients suffering from severe emphysema. The company’s flagship therapy, the Zephyr® Endobronchial Valve System, employs one-way valves delivered via a minimally invasive bronchoscopic procedure to collapse diseased portions of the lung, reducing hyperinflation and improving respiratory function. Complementing this treatment, Pulmonx offers the Chartis® Pulmonary Assessment System, which provides clinicians with quantitative measurements of collateral ventilation to aid in patient selection and optimize clinical outcomes.

The Zephyr Valve received the CE mark in Europe in 2008 and FDA approval in the United States in 2018, and it has since been adopted by leading respiratory and thoracic centers across North America and Europe.